A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life
Tekijät: Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT
Kustantaja: MOSBY, INC
Julkaisuvuosi: 2006
Journal: Clinical Pharmacology and Therapeutics
Tietokannassa oleva lehden nimi: CLINICAL PHARMACOLOGY & THERAPEUTICS
Lehden akronyymi: CLIN PHARMACOL THER
Vuosikerta: 80
Numero: 5
Aloitussivu: 502
Lopetussivu: 508
Sivujen määrä: 7
ISSN: 0009-9236
DOI: https://doi.org/10.1016/j.clpt.2006.07.008
Tiivistelmä
Conclusion: Oral voriconazole, but not terbinafine, markedly inhibited the metabolism of alfentanil. Caution should be exercised when alfentanil is given to patients receiving voriconazole. It is reasonable to assume that patients receiving voriconazole require 70% to 90% less alfentanil for the maintenance of analgesia than patients who are not receiving concomitant CYP3A inhibitors.
Conclusion: Oral voriconazole, but not terbinafine, markedly inhibited the metabolism of alfentanil. Caution should be exercised when alfentanil is given to patients receiving voriconazole. It is reasonable to assume that patients receiving voriconazole require 70% to 90% less alfentanil for the maintenance of analgesia than patients who are not receiving concomitant CYP3A inhibitors.
Turun yliopiston Tutkimustietojärjestelmän portaali